VALENCIA, Spain, April 14, 2026 /PRNewswire/ --  ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced its participation in the 25^th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.

Company management will meet with investors in one-on-one meetings during the conference.

About ARTHEx Biotech

ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform, BOOST-ONÔ, pairs selective oligonucleotides with enhanced tissue delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.

The Company headquarters are in Valencia, Spain.

For more information on ArthemiR™, please visit https://www.arthemir.com or https://clintrials.gov.  For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-announces-participation-at-the-25th-annual-needham-virtual-healthcare-conference-302741229.html

SOURCE ARTHEx Biotech